CD8A and type 1 diabetes mellitus: This remains a critical issue for Treg-ACT applications in the context of T1D, as Tregs must be able to migrate to sites of inflammation and priming, specifically to the pancreatic draining lymph nodes where recent studies have revealed the presence of a stem-cell like CD8+ T cell progenitor population that significantly contributes to pancreatic β-cell destruction in the NOD model of T1D (67).